2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。基本信息 | 登录收藏 | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | CURRENT CANCER DRUG TARGETS CURR CANCER DRUG TAR (此期刊被最新的JCR期刊SCIE收录) LetPub评分 6.6
53人评分
我要评分
声誉 7.6 影响力 5.2 速度 8.9 | |||||||||||||||||||||||||||||
期刊ISSN | 1568-0096 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||||||
E-ISSN | 1873-5576 | |||||||||||||||||||||||||||||
2023-2024最新影响因子 (数据来源于搜索引擎) | 2.3 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||
实时影响因子 | 截止2024年10月29日:2.58 | |||||||||||||||||||||||||||||
2023-2024自引率 | 0.00%点击查看自引率趋势图 | |||||||||||||||||||||||||||||
五年影响因子 | 3.1 | |||||||||||||||||||||||||||||
JCI期刊引文指标 | 0.45 | |||||||||||||||||||||||||||||
h-index | 85 | |||||||||||||||||||||||||||||
CiteScore ( 2024年最新版) |
| |||||||||||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||||||||||
期刊官方网站 | http://benthamscience.com/journal/index.php?journalID=ccdt | |||||||||||||||||||||||||||||
期刊投稿网址 | http://bsp-cms.eurekaselect.com/index.php/CCDT | |||||||||||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足CURRENT CANCER DRUG TARGETS的语言要求,还能让CURRENT CANCER DRUG TARGETS编辑和审稿人得到更好的审稿体验,让稿件最大限度地被CURRENT CANCER DRUG TARGETS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||||||||||
是否OA开放访问 | No | |||||||||||||||||||||||||||||
通讯方式 | BENTHAM SCIENCE PUBL LTD, EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, SHARJAH, U ARAB EMIRATES, 1200 BR | |||||||||||||||||||||||||||||
出版商 | Bentham Science Publishers B.V. | |||||||||||||||||||||||||||||
涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||||||||||
出版国家或地区 | NETHERLANDS | |||||||||||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||||||||||
出版周期 | Bimonthly | |||||||||||||||||||||||||||||
出版年份 | 2001 | |||||||||||||||||||||||||||||
年文章数 | 70点击查看年文章数趋势图 | |||||||||||||||||||||||||||||
Gold OA文章占比 | 1.92% | |||||||||||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 55.71% | |||||||||||||||||||||||||||||
WOS期刊SCI分区 ( 2023-2024年最新版) | WOS分区等级:3区
| |||||||||||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2023年12月最新升级版) | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2022年12月升级版) |
| |||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2021年12月旧的升级版) |
| |||||||||||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1568-0096%5BISSN%5D | |||||||||||||||||||||||||||||
平均审稿速度 | 网友分享经验: 平均1月 | |||||||||||||||||||||||||||||
平均录用比例 | 网友分享经验: 约50% | |||||||||||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在CURRENT CANCER DRUG TARGETS顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 | |||||||||||||||||||||||||||||
期刊常用信息链接 |
|
|
|
中国学者近期发表的论文 | |
1. | Combined Immunotherapy and Targeted Therapies for Cancer Treatment: Recent Advances and Future Perspectives Author: Zhang, Yan; Li, Yafei; Fu, Qiuxia; Han, Zhiqiang; Wang, Daijie; Shinge, Shafiu A. Umar; Muluh, Tobias Achu; Lu, Xiaohong Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 4, pp. 251-264. DOI: 10.2174/1568009623666221020104603 PubMed DOI |
2. | Phosphoserine Aminotransferase 1: A Metabolic Enzyme Target of Cancers Author: Yang, Xue; Li, Chaojie; Chen, Yuping Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 3, pp. 171-186. DOI: 10.2174/1568009622666220829105300 PubMed DOI |
3. | Combinatorial Application of Papain and CD66B for Isolating Glioma-Associated Neutrophils Author: Xu, Xing; Yang, Yongchang; Liu, Yancheng; Ge, Xianglian; Yi, Tailong; Xie, Yang; Ning, Chunlan; Shen, Shengfu; Sun, Zengfeng; Zhang, Zhen; Zhai, Qiongli; Wang, Xiaoguang; Meng, Xianghui; Dong, Jun; Huang, Qiang; Yang, Xuejun; Li, Wenliang; Jin, Xun Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 5, pp. 400-411. DOI: 10.2174/1568009623666221027101637 PubMed DOI |
4. | Polyphyllin VII as a Potential Drug for Targeting Stemness in Hepatocellular Cancer via STAT3 Signaling Author: Xu, Liuhang; Chen, Ziqi; Wang, Yangbin; Li, Yulin; Wang, Zhongyu; Li, Fangzhou; Xi, Xueyan Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 4, pp. 325-331. DOI: 10.2174/1568009623666221024103834 PubMed DOI |
5. | HIF-1 alpha/Malat1/miR-141 Axis Activates Autophagy to Increase Proliferation, Migration, and Invasion in Triple-negative Breast Cancer Author: Xu, Fangyuan; Hu, Yue; Gao, Jie; Wang, Jianxiong; Xie, Yujie; Sun, Fuhua; Wang, Li; Miyamoto, Akira; Xia, Ou; Zhang, Chi Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 5, pp. 363-378. DOI: 10.2174/1568009623666221228104833 PubMed DOI |
6. | Present and Future Prospects of the Anti-cancer Activities of Saikosaponins Author: Xiao, Li-Xia; Zhou, Hui-Nian; Jiao, Zuo-Yi Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 1, pp. 2-14. DOI: 10.2174/1568009622666220806121008 PubMed DOI |
7. | Genome-Wide CRISPR-Cas9 Screening and Identification of Potential Genes Promoting Prostate Cancer Growth and Metastasis Author: Wang, Wei; Yuan, Dongbo; Jiang, Kehua; Li, Ruidong; Qu, Han; Jiang, Fu-Neng; Zhong, Wei-De; Sun, Fa; Jia, Zhenyu; Zhu, Jianguo Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 1, pp. 71-86. DOI: 10.2174/1568009622666220615154137 PubMed DOI |
8. | Geiparvarin Inhibits the Progression of Osteosarcoma by Down-regulating COX2 Expression Author: Wang, Bin; Du, Jia; Zhang, Zhiming; Huang, Ping; Chen, Shu; Zou, Hua Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 5, pp. 379-387. DOI: 10.2174/1568009623666221208113432 PubMed DOI |
9. | Up-regulation of Core 1 Beta 1, 3-Galactosyltransferase Suppresses Osteosarcoma Growth with Induction of IFN-gamma Secretion and Proliferation of CD8(+) T Cells Author: Tang, Lei; Fu, Cegang; Zhao, Hongwei; Wang, Bofei; Jia, Siyu; Chen, Haidan; Cai, Huili Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 4, pp. 265-277. DOI: 10.2174/1568009622666221010105701 PubMed DOI |
10. | RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells Author: Suthe, Sreedhar Reddy; Yao, Hang-Ping; Weng, Tian-Hao; Wang, Ming-Hai Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 2, pp. 103-117. DOI: 10.2174/1568009622666220825115528 PubMed DOI |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室